Read more
This succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and diagnostic criteria, international experts have assembled to convey the most up-to-date knowledge in this rapidly evolving field. The opening chapters cover the diagnosis and classification, genetics, cytogenetic findings, and prognostic factors of MPNs. Further chapters explore therapies specific to the different disease entities, including polycythemia vera, essential thrombocytopenia, myelofibrosis, and eosinophilic disorders, and mastocytosis. Unique areas of discussion include JAK2 inhibitor therapy, hematopoietic stem cell transplantation, and blastic transformation. A valuable reference for practicing hematologists, this forefront book enriches our understanding of recent discoveries and their impact on conventional and investigational treatments.
List of contents
Chapter 1 - Diagnosis and Classification of the BCR-ABL- negative Myeloproliferative Neoplasms.- Chapter 2 - Genetics of the Myeloproliferative Neoplasms.- Chapter 3 - Cytogenetic Findings in Classic Myeloproliferative Neoplasms.- Chapter 4 - Prognostic Factors in Classic Myeloproliferative Neoplasms.- Chapter 5 - Therapy of Polycythemia Vera and Essential Thrombocythemia.- Chapter 6 - Conventional and Investigational Therapy for Primary Myelofibrosis.- Chapter 7 - Hematopoietic Cell Transplantation for Myelofibrosis.- Chapter 8 - JAK2 Inhibitors as Therapy for Classic Myeloproliferative Neoplasms.- Chapter 9 - Blastic Transformation of Classic Myeloproliferative Neoplasms.- Chapter 10 - Eosinophilic Disorders: Differential Diagnosis and Management.- Chapter 11 - Pathogenesis, Diagnosis, Classification, and Management of Systemic Mastocytosi.
Summary
This succinct resource provides an ideal balance of the biology and practical therapeutic strategies for classic and non-classic BCR-ABL-negative myeloproliferative neoplasms. Utilizing current World Health Organization nomenclature, classification, and diagnostic criteria, international experts have assembled to convey the most up-to-date knowledge in this rapidly evolving field. The opening chapters cover the diagnosis and classification, genetics, cytogenetic findings, and prognostic factors of MPNs. Further chapters explore therapies specific to the different disease entities, including polycythemia vera, essential thrombocytopenia, myelofibrosis, and eosinophilic disorders, and mastocytosis. Unique areas of discussion include JAK2 inhibitor therapy, hematopoietic stem cell transplantation, and blastic transformation. A valuable reference for practicing hematologists, this forefront book enriches our understanding of recent discoveries and their impact on conventional and investigational treatments.
